These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 15766280)

  • 61. Pumping of drugs by P-glycoprotein: a two-step process?
    Litman T; Skovsgaard T; Stein WD
    J Pharmacol Exp Ther; 2003 Dec; 307(3):846-53. PubMed ID: 14534356
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Substituted tetrahydroisoquinoline compound B3 inhibited P-glycoprotein-mediated multidrug resistance in-vitro and in-vivo.
    Fang W; Li Y; Cai Y; Kang K; Yan F; Liu G; Huang W
    J Pharm Pharmacol; 2007 Dec; 59(12):1649-55. PubMed ID: 18053326
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Influence of combinations of digitonin with selected phenolics, terpenoids, and alkaloids on the expression and activity of P-glycoprotein in leukaemia and colon cancer cells.
    Eid SY; El-Readi MZ; Eldin EE; Fatani SH; Wink M
    Phytomedicine; 2013 Dec; 21(1):47-61. PubMed ID: 23999162
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Euphorbiasteroid reverses P-glycoprotein-mediated multi-drug resistance in human sarcoma cell line MES-SA/Dx5.
    Choi JS; Kang NS; Min YK; Kim SH
    Phytother Res; 2010 Jul; 24(7):1042-6. PubMed ID: 19960428
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Secretion of lysosomal enzymes by drug-sensitive and multiple drug-resistant cells.
    Warren L; Jardillier JC; Ordentlich P
    Cancer Res; 1991 Apr; 51(8):1996-2001. PubMed ID: 1672622
    [TBL] [Abstract][Full Text] [Related]  

  • 66. A flow cell assay for evaluation of whole cell drug efflux kinetics: analysis of paclitaxel efflux in CCRF-CEM leukemia cells overexpressing P-glycoprotein.
    Lin JT; Sharma R; Grady JJ; Awasthi S
    Drug Metab Dispos; 2001 Feb; 29(2):103-10. PubMed ID: 11159798
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Overexpression of caveolin-1 increases plasma membrane fluidity and reduces P-glycoprotein function in Hs578T/Dox.
    Cai C; Zhu H; Chen J
    Biochem Biophys Res Commun; 2004 Jul; 320(3):868-74. PubMed ID: 15240128
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Increased accumulation of drugs in multidrug-resistant cells induced by liposomes.
    Warren L; Jardillier JC; Malarska A; Akeli MG
    Cancer Res; 1992 Jun; 52(11):3241-5. PubMed ID: 1591733
    [TBL] [Abstract][Full Text] [Related]  

  • 69. First characterization of fish P-glycoprotein (abcb1) substrate specificity using determinations of its ATPase activity and calcein-AM assay with PLHC-1/dox cell line.
    Zaja R; Lončar J; Popovic M; Smital T
    Aquat Toxicol; 2011 May; 103(1-2):53-62. PubMed ID: 21392495
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Can flavonoids from honey alter multidrug resistance?
    Jaganathan SK
    Med Hypotheses; 2011 Apr; 76(4):535-7. PubMed ID: 21247706
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Deactivation of P-glycoprotein by a novel compound, oxalyl bis (N-phenyl) hydroxamic acid.
    Choudhuri SK
    Neoplasma; 2002; 49(4):272-7. PubMed ID: 12382028
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The multi-drug resistance reversal agent SR33557 and modulation of vinca alkaloid binding to P-glycoprotein by an allosteric interaction.
    Martin C; Berridge G; Higgins CF; Callaghan R
    Br J Pharmacol; 1997 Oct; 122(4):765-71. PubMed ID: 9375975
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Overexpression of MDR1 in an intestinal cell line results in increased cholesterol uptake from micelles.
    Tessner TG; Stenson WF
    Biochem Biophys Res Commun; 2000 Jan; 267(2):565-71. PubMed ID: 10631102
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Inhibition of P-glycoprotein function by tea catechins in KB-C2 cells.
    Kitagawa S; Nabekura T; Kamiyama S
    J Pharm Pharmacol; 2004 Aug; 56(8):1001-5. PubMed ID: 15285844
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Optimizing chemotherapy by measuring reversal of P-glycoprotein activity in plasma membrane vesicles.
    Köhler S; Stein WD
    Biotechnol Bioeng; 2003 Mar; 81(5):507-17. PubMed ID: 12514799
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Membrane microparticles mediate transfer of P-glycoprotein to drug sensitive cancer cells.
    Bebawy M; Combes V; Lee E; Jaiswal R; Gong J; Bonhoure A; Grau GE
    Leukemia; 2009 Sep; 23(9):1643-9. PubMed ID: 19369960
    [TBL] [Abstract][Full Text] [Related]  

  • 77. P-glycoprotein is implicated in the inhibition of ceramide-induced apoptosis in TF-1 acute myeloid leukemia cells by modulation of the glucosylceramide synthase pathway.
    Turzanski J; Grundy M; Shang S; Russell N; Pallis M
    Exp Hematol; 2005 Jan; 33(1):62-72. PubMed ID: 15661399
    [TBL] [Abstract][Full Text] [Related]  

  • 78. A new generation of MDR modulating agents with dual activity: P-gp inhibitor and iNOS inducer agents.
    Colabufo NA; Contino M; Berardi F; Perrone R; Panaro MA; Cianciulli A; Mitolo V; Azzariti A; Quatrale A; Paradiso A
    Toxicol In Vitro; 2011 Feb; 25(1):222-30. PubMed ID: 21078380
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Effect of the modulation of the membrane lipid composition on the localization and function of P-glycoprotein in MDR1-MDCK cells.
    Kamau SW; Krämer SD; Günthert M; Wunderli-Allenspach H
    In Vitro Cell Dev Biol Anim; 2005; 41(7):207-16. PubMed ID: 16223335
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The glycosylation and orientation in the membrane of the third cytoplasmic loop of human P-glycoprotein is affected by mutations and substrates.
    Loo TW; Clarke DM
    Biochemistry; 1999 Apr; 38(16):5124-9. PubMed ID: 10213617
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.